Sanofi (ETR:SNW)
| Market Cap | 95.74B -22.4% |
| Revenue (ttm) | 46.72B +5.5% |
| Net Income | 7.81B +40.5% |
| EPS | 6.40 +44.2% |
| Shares Out | n/a |
| PE Ratio | 12.25 |
| Forward PE | 9.46 |
| Dividend | 3.92 (4.95%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 15,592 |
| Average Volume | 20,324 |
| Open | 79.41 |
| Previous Close | 79.22 |
| Day's Range | 79.29 - 80.47 |
| 52-Week Range | 76.43 - 110.82 |
| Beta | 0.40 |
| RSI | 49.04 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial StatementsNews
Sanofi (SNY) Gains Positive EU Nod for Rezurock Approval
Sanofi (SNY) Gains Positive EU Nod for Rezurock Approval
Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News
This vaccine-focused biotech reported a significant insider sale as it advances its hepatitis B franchise and global partnerships.
Sanofi graft-versus-host disease asset Rezurock gains EU approval recommendation
Sanofi Announces Positive CHMP Opinion For Rezurock In EU
PARIS (dpa-AFX) - Sanofi (SNY), Thursday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the condi...
Sanofi (SNY) Gains EU Panel Support for Rezurock Approval
Sanofi (SNY) Gains EU Panel Support for Rezurock Approval
Regeneron posts Q4 beat as Sanofi collaboration offsets Eylea headwinds
Press Release: Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world ev...
Sanofi SA (SNY) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ...
Sanofi SA (SNY) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Acquisitions Propel Performance
Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript
Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript
Q4 2025 Sanofi SA Earnings Call Transcript
Q4 2025 Sanofi SA Earnings Call Transcript
Sanofi Creeps Higher On 'Essentially In Line' Guidance For 2026
Sanofi stock rose slightly early Thursday on better-than-expected earnings and in line guidance for the current year.
Sanofi 2025 Q4 - Results - Earnings Call Presentation
Sanofi (SNY) Projects Profitable Growth and Announces Share Buyback for 2026
Sanofi (SNY) Projects Profitable Growth and Announces Share Buyback for 2026
Sanofi (SNY) Reports Strong EPS Growth and Sales Performance
Sanofi (SNY) Reports Strong EPS Growth and Sales Performance
Sanofi Warns Dupixent Is Too Big To Replace As Patent Clock Ticks
Sanofi SA (NASDAQ: SNY) reported fourth-quarter sales of $13.159 billion (11.30 billion euros) on Thursday, missing the consensus of $13.41 billion . Sales increased 7% year over year, up 13.3% in co...
Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
Drugmakers Roche and Sanofi posted full-year earnings that matched expectations and did little to move either stock. As pharma companies face a "patent cliff" where existing drugs lose exclusivity, th...
Earnings Scheduled For January 29, 2026
Companies Reporting Before The Bell • MOGU (NYSE: MOGU) is estimated to report earnings for its first quarter. • Trane Technologies (NYSE: TT) is likely to report quarterly earnings at $2.82 per sha...
Sanofi (SNY) Surpasses Earnings Expectations with Strong Dupixent Sales
Sanofi (SNY) Surpasses Earnings Expectations with Strong Dupixent Sales
Sanofi anticipates profitable growth to continue over at least five years
Sanofi Posts Q4 Loss, Sees Continued Profitable Growth In FY26; Plans EUR 1 Bln Buyback
(RTTNews) - French drug major Sanofi (SNY) reported Thursday a loss in its fourth quarter, compared to prior year's profit, despite higher net sales. Looking ahead for fiscal 2026, the company still p...
Sanofi to Launch $1.20 Billion Share Buyback
The buyback comes as the French drugmaker said that its sales and earnings for the fourth quarter rose.
Sanofi (SNY) Reports Strong Q4 Earnings with Significant EPS and Revenue Beat
Sanofi (SNY) Reports Strong Q4 Earnings with Significant EPS and Revenue Beat
Sanofi Non-GAAP EPS of €1.53 beats by €0.68, revenue of €11.3B beats by €170M; issues FY26 outlook
Sanofi press release (SNY): Q4 Non-GAAP EPS of €1.53 beats by €0.68. Revenue of €11.3B (+7.0% Y/Y) beats by €170M. Pharma launches increased sales by 49.4%
Sanofi: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026
2025: strong sales and EPS growth.Continued profitable growth expected in 2026 Paris, January 29, 2026 Q4 sales growth of 13.3% at CER1 and business earnings per share (EPS)2 of €1.53 Pharma launc...
Sanofi targets high single digit sales growth in 2026, plans share buyback
French drugmaker Sanofi said on Thursday it expects sales to grow by a high-single-digit percentage in 2026, banking on strong demand for its blockbuster asthma drug Dupixent and some newer medicines.